

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/572,706-Conf. #4535
				Filing Date	January 8, 2007
				First Named Inventor	Peter Hansen
				Art Unit	1625
				Examiner Name	Z. N. Davis
Sheet	1	of	2	Attorney Docket Number	15652-08500-US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
	AA*	US-2004/0235761-A1	11-25-2004	Furuta et al.	
	AB*	US-2005/0101590-A1	05-12-2005	Yasui et al.	
	AC*	US-6,979,690-B2	12-27-2005	Gymer et al.	
	AD*	US-2006/0035938-A1	02-16-2006	Bladh et al.	
	AE*	US-2006/0211695-A1	09-21-2006	Borzilleri et al.	
	AF*	US-2006/0270666-A1	11-30-2006	Bladh et al.	
	AG*	US-2007/0010551-A1	01-11-2007	Bladh et al.	
	AH*	US-2007/0043036-A1	02-22-2007	Hansen et al.	
	AI*	US-2007/0213323-A1	09-13-2007	Imogai et al.	
	AJ*	US-2009/0131486-A1	05-21-2009	Hansen et al.	
	AK*	US Ser. No. 12/895,995	-	Muragan et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-2003/070277-A1	08-28-2003	Shionogi & Co, Ltd.		See US2005/0101590
	BB	WO-2006/030032-A1	03-23-2006	Janssen Pharmaceutica NV and Addex Pharmaceuticals S. A.		
	BC	WO-2006/116713-A1	11-02-2006	Amgen Inc		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/572,706-Conf. #4535
				Filing Date	January 8, 2007
				First Named Inventor	Peter Hansen
				Art Unit	1625
				Examiner Name	Z. N. Davis
Sheet	2	of	2	Attorney Docket Number	15652-08500-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	EISTERT, B., <i>et al.</i> , "Synthese und Reaktionen substituierter Pyrrolin-2,3-dione mit Diazoalkanen," <i>Liebigs Ann. Chem.</i> (1976), pp. 1023-1030.	See Abstract
	CB	WRIGHT, J.L., <i>et al.</i> , "A neutrophil elastase inhibitor reduces cigarette smoke-induced remodelling of lung vessels," <i>Eur Respir J</i> (2003), Vol. 22, pp. 77-81.	
	CC	Office Action dated 04/09/08; Ser. No. 10/569,923 (Publication No. 2006/0270666).	
	CD	Office Action dated 12/12/08; Ser. No. 10/569,923 (Publication No. 2006/0270666).	
	CE	Restriction Requirement dated 02/28/08; Ser. No. 10/534,720 (Publication No. 2006/0035938).	
	CF	Office Action dated 06/23/08; Ser. No. 10/534,720 (Publication No. 2006/0035938).	
	CG	Office Action dated 01/02/09; Ser. No. 10/534,720 (Publication No. 2006/0035938).	
	CH	Interview Summary dated 07/14/09; Ser. No. 10/534,720 (Publication No. 2006/0035938).	
	CI	Office Action dated 09/29/08; Ser. No. 10/569,571 (Publication No. 2007/0010551).	
	CJ	Office Action dated 03/16/09; Ser. No. 10/569,571 (Publication No. 2007/0010551).	
	CK	Interview Summary dated 09/28/09; Ser. No. 10/569,571 (Publication No. 2007/0010551).	
	CL	Restriction Requirement dated 01/21/09; Ser. No. 10/572,640 (Publication No. 2007/0043036).	
	CM	Interview Summary dated 08/04/09; Ser. No. 10/572,640 (Publication No. 2007/0043036).	
	CN	Restriction Requirement dated 08/25/09; Ser. No. 12/299,879 (Publication No. 2009/0131486).	
	CO	Office Action dated 12/28/09; Ser. No. 12/299,879 (Publication No. 2009/0131486).	
	CP	Office Action dated 06/24/10; Ser. No. 12/299,879 (Publication No. 2009/0131486).	
	CQ	Notice of Allowance and Interview Summary dated 09/23/10; Ser. No. 12/299,879 (Publication No. 2009/0131486).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.